# US 2015/0105265 A1 · Methods to assess the likelihood of dysplasia or esophageal adenocarcinoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105265 A1
- Document ID: US20150105265A1
- Status: Published application
- Kind: A1
- Application number: 14/402,061
- Filed: 2013-05-17
- Published: 2015-04-16
- Earliest claimed: 2012-05-18
- Assignees: Medical Research Council
- Applicants: Medical Research Council
- Inventors: Rebecca Fitzgerald; Muhammad Alvi; Xinxue Liu
- Web page: https://patentgrep.com/patent/US20150105265A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/154: Methylation markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

In some embodiments, a method for aiding assessment of the likelihood of dysplasia or esophageal adenocarcinoma being present in a subject can include (a) providing an esophagal sample from said subject (b) determining the methylation status of (i) SLC22A18, (ii) PIGR, (iii) GJA12 and (iv) RIN2 in said sample wherein if 2 or more of said genes are methylated then an increased likelihood of presence of dysplasia or esophageal is determined. The invention also relates to apparatus for same.

## Claims

### Claim 1

A method for aiding assessment of the likelihood of dysplasia or esophagal adenocarcinoma being present in a subject, the method comprising
(a) providing an esophagal sample from said subject
(b) determining the methylation status of
(i) SLC22A18,
(ii) PIGR,
(iii) GJA12 and
(iv) RIN2
in said sample
wherein if 2 or more of said genes are methylated then an increased likelihood of presence of dysplasia or esophagal adenocarcinoma is determined.

### Claim 2 (depends on 1)

A method according to claim 1 wherein the method further comprises determining the methylation status of (v) TCEAL7.

### Claim 3 (depends on 1)

A method according to claim 1 wherein if said subject is male, the method further comprises determining the methylation status of (vi) RGN.

### Claim 4 (depends on 1)

A method according to claim 1 wherein the dysplasia is high grade dysplasia (HGD).

### Claim 5 (depends on 1)

A method of assessing the risk for a particular subject comprising performing the method according to claim 1, wherein if 0 or 1 of said genes are methylated then low risk is determined, and if 2 of said genes are methylated then intermediate risk is determined, if 3 or more of said genes are methylated then high risk is determined.

### Claim 6 (depends on 1)

A method according to claim 1 wherein methylation status is determined by pyrosequencing.

### Claim 7 (depends on 6)

A method according to claim 6 wherein said pyrosequencing is carried out using one or more sequencing primers selected from Supplementary Table 5.

### Claim 8 (depends on 1)

A method according to claim 1 wherein the methylation status is scored by determining the percentage methylation of each of said genes and comparing the values to the following methylation cut off percentages:
Gene Methylation cut-off (%)
GJA12 51.74000
SLC22A18 49.25000
PIGR 64.755000
RIN2 37.85500
RGN (males only) 18.645000
TCEAL7 58.54000
wherein a value for a gene which exceeds the methylation cut off percentage for said gene is scored as ‘methylated’.

### Claim 9

An apparatus or system which is
(a) configured to analyse an esophagal sample from a subject, wherein said analysis comprises
(b) determining the methylation status of
(i) SLC22A18,
(ii) PIGR,
(iii) GJA12 and
(iv) RIN2
in said sample,
said apparatus or system comprising an output module,
wherein if 2 or more of said genes are methylated then an increased likelihood of presence of dysplasia or esophagal adenocarcinoma is determined.

### Claim 10 (depends on 9)

An apparatus according to claim 9 wherein the analysis further comprises determining the methylation status of (v) TCEAL7.

### Claim 11 (depends on 9)

An apparatus according to claim 9 wherein if said subject is male, the analysis further comprises determining the methylation status of (vi) RGN.

### Claim 12 (depends on 1)

A method according to claim 1 wherein said sample comprises frozen biopsy material.

### Claim 13

A method for aiding assessment of the likelihood of dysplasia or esophagal adenocarcinoma being present in a subject, the method comprising
(a) providing an esophagal sample from said subject
(b) determining the methylation status of
(i) SLC22A18,
(ii) PIGR,
(iii) GJA12 and
(iv) RIN2
in said sample;
comparing the methylation values of (b) to a reference standard,
wherein if 2 or more of said genes are methylated at a level higher than the reference standard then an increased likelihood of presence of dysplasia or esophagal adenocarcinoma is determined.

### Claim 14 (depends on 13)

A method according to claim 13 wherein said reference standard is from a subject having Barrett's esophagus, but not having dysplasia or esophagal adenocarcinoma.

### Claim 15 (depends on 13)

A method according to claim 13 wherein said reference standard comprises columnar epithelium such as Barrett's esophagus or duodenum.

### Claim 16 (depends on 13)

A method according to claim 13 wherein the method further comprises determining the methylation status of (v) TCEAL7.

### Claim 17 (depends on 13)

A method according to claim 13 wherein if said subject is male, the method further comprises determining the methylation status of (vi) RGN.

### Claim 18 (depends on 1)

A computer program product operable, when executed on a computer, to perform the method steps of claim 1.

### Claim 19

(canceled)
